Pipeline

Filter by:
All disease areas
  • All disease areas
  • Alzheimer's Disease
  • Amyotrophic Lateral Sclerosis (ALS)
  • Brain Contusion
  • Epilepsy
  • Essential Tremor
  • Lupus
  • Major depressive disorder (MDD)
  • Multiple Sclerosis (MS)
  • Multiple System Atrophy (MSA)
  • Ophthalmology
  • Pain
  • Parkinson's Disease
  • Postpartum Depression (PPD)
  • Schizophrenia
  • Spinal Muscular Atrophy (SMA)
  • Stroke
  • Various immunologic conditions
All phases
  • All phases
  • Filed
  • Phase 3
  • Phase 2
  • Phase 1
Phase
  • 1Phase 1
  • 2 Phase 2
  • 3Phase 3
  • Filed
  • Aducanumab (Aβ mAb)

    Alzheimer’s disease

    Developed in collaboration with Eisai Co., Ltd.

    Licensed from Neurimmune.

    Alzheimer’s disease (AD) is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability. It is estimated that more than 25 million individuals are living with AD worldwide1.

    Today we understand that AD is a continuum with a long silent phase that begins years before symptoms appear. As AD progresses, symptoms like memory loss, personality and behavioral changes commonly associated with AD begin to manifest.

    How this investigational therapy could help:

    The memory loss and functional decline of Alzheimer’s disease have been linked to amyloid plaques, abnormal protein deposits that build up in the brain. Aducanumab is an antibody that binds to and may reduce amyloid plaques from the brain, potentially slowing the progress of the disease.

    Learn more about EMERGE and ENGAGE, clinical trials for Alzheimer’s disease.

     

    1 World Health Organization Dementia a Public Health Priority. http://www.who.int/mental_health/publications/dementia_report_2012/en/. Accessed 23 May 2016.

  • BIIB067 (tofersen)

    SOD-1-Amyotrophic lateral sclerosis (ALS)

    Developed in collaboration with Ionis Pharmaceuticals.

    ALS is a progressive neurodegenerative disease that results in the loss of motor neurons in the brain and the spinal cord. Motor neurons provide the ability to move, speak, swallow, and breathe. As the disease progresses, ALS patients gradually lose these abilities.

    How this investigational therapy could help: 

    In a rare form of ALS, a mutated protein called superoxide dismutase (SOD1) has been associated with the degeneration of motor neurons. SOD1-ALS is the second most common form of inherited or familial ALS, accounting for up to 20 percent of familial ALS and 2 percent of all ALS cases. 

    BIIB067 (tofersen) is thought to reduce the production of SOD1 protein and is being evaluated to see if it can potentially slow the fatal progression of SOD1-ALS.

  • BIIB093 (IV glibenclamide)

    Large hemispheric infarction

    It is estimated that nearly two million people in the United States and the European Union will have a stroke each year. Stroke is a leading cause of mortality and serious long-term disability. There is a substantial unmet medical need for new therapies that can improve outcomes in acute stroke. The target indication for BIIB093 (IV glibenclamide) is large hemispheric infarction (LHI), a severe form of ischemic stroke where brain swelling (cerebral edema) often leads to a disproportionately large share of stroke-related morbidity and mortality.

     

    How this investigational therapy could help:

    In pre-clinical studies, BIIB093 (IV glibenclamide) has been shown to block SUR1-TRPM4 channels that mediate stroke related brain swelling. Clinical proof-of-concept studies have demonstrated the potential of BIIB093 to reduce brain swelling, disability and the risk of death in patients with LHI.

  • Lecanemab (Aβ mAb)

    Alzheimer’s disease

    Developed in collaboration with Eisai Co., Ltd.

    Alzheimer’s disease (AD) is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability. It is estimated that more than 25 million individuals are living with AD worldwide1.

    Today we understand that AD is a continuum with a long silent phase that begins years before symptoms appear. As AD progresses, symptoms like memory loss, personality and behavioral changes commonly associated with AD begin to manifest.

    How this investigational therapy could help:

    The memory loss and functionality decline of Alzheimer’s disease have been linked to amyloid plaques, abnormal protein deposits that build up in the brain. Lecanemab (Aβ mAb) is an antibody that binds to amyloid, which could reduce its presence in the brain and potentially slow the progress of the disease.

     

    1 World Health Organization Dementia a Public Health Priority. http://www.who.int/mental_health/publications/dementia_report_2012/en/. Accessed 23 May 2016.

  • SB15 (biosimilar referencing EYLEA®)

    Various ophthalmologic conditions

    *Licensed from Samsung Bioepis

    SB15 is a proposed biosimilar of the reference product aflibercept (EYLEA®).  EYLEA is widely used to treat ophthalmologic conditions such as neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR) in patients with DME and myopic choroidal neovascularization (CNV).

    How this therapy could help:

    Biosimilars play a key role in helping generate meaningful savings for payers and health systems globally, while enabling increased access for patients to biologic therapies.  Biosimilars help create the budgetary headroom necessary to fund future innovations for society. 

    Learn more about the SB15 clinical trial.

  • Dapirolizumab pegol (anti-CD40L)

    Systemic lupus erythematosus

    Developed in collaboration with UCB, Inc.

    This chronic inflammatory disease occurs when the body’s own immune system mistakenly attacks healthy tissue in skin, joints, kidneys, the brain and other organs. It is a difficult disease to diagnose because it resembles several other conditions.

    How this investigational therapy could help:

    CD40L is a protein in B and T cells, which helps regulate the immune system. Dapirolizumab pegol (anti-CD40L) is an antibody that blocks CD40L, potentially lessening disease activity in lupus patients.

    Learn more about the PHOENYCS GO and PHOENYCS GLIDE clinical trials.

  • BIIB059 (anti-BDCA2)

    Systemic lupus erythematosus

    This chronic inflammatory disease occurs when the body’s own immune system mistakenly attacks healthy tissue in skin, joints, kidneys, the brain and other organs. It is a difficult disease to diagnose because it resembles several other conditions.

    How this investigational therapy could help:

    BDCA2 is a protein present in specific cells within the immune system. An antibody against BDCA2 can potentially interrupt production of interferons, inflammatory molecules that are increased in patients with lupus and contribute to disease activity. 

    Learn more about TOPAZ-1 and TOPAZ-2, clinical trials for systemic lupus erythematosus.

  • BIIB125 (zuranolone)

    Major depressive disorder (MDD)

    Developed in collaboration with Sage Therapeutics, Inc.

    Major depressive disorder (MDD) is a common but serious mood disorder in which people experience depressive symptoms that impair their social, occupational, educational or other important functioning, such as a depressed mood or loss of interest or pleasure in daily activities, consistently for at least a two-week period. It is estimated that approximately 17 million people in the U.S. and more than 250 million people worldwide suffer from MDD each year.

    Why we believe this investigational drug has the potential to help:

    Zuranolone is an investigational oral neuroactive steroid GABA-A receptor positive allosteric modulator. The GABA system is the major inhibitory signaling pathway of the brain and central nervous system and contributes significantly to regulating brain function.

  • BIIB125 (zuranolone)

    Postpartum depression (PPD)

    Developed in collaboration with Sage Therapeutics, Inc.

    Postpartum depression is a major depressive episode that can occur during pregnancy or postpartum and is one of the most common medical complications during and after pregnancy. In the U.S., an estimated 1 in 8 mothers experience symptoms of PPD, which equates to approximately 500,000 annual cases.

    Why we believe this investigational drug has the potential to help:

    Zuranolone is an investigational oral neuroactive steroid GABA-A receptor positive allosteric modulator. The GABA system is the major inhibitory signaling pathway of the brain and central nervous system, and contributes significantly to regulating brain function.

  • BIIB800 (biosimilar referencing ACTEMRA®, BAT1806)

    Various immunologic conditions

    Licensed from Bio-Thera Solutions, Ltd.

    BIIB800 (BAT1806) is a proposed biosimilar of the reference product referencing ACTEMRA®/RoACTEMRA® (tocilizumab).  ACTEMRA/RoACTEMRA’s primary indication is for moderate to severe rheumatoid arthritis in adults as well as juvenile idiopathic polyarthritis, systemic juvenile idiopathic arthritis, giant cell arteritis and cytokine release syndrome.

    Why we believe this investigational drug has the potential to help:

    Biosimilars play a key role in helping to generate meaningful savings for payers and health systems globally, while enabling increased access for patients to biologic therapies.  Biosimilars help drive healthcare sustainability, creating the budgetary headroom necessary to fund future innovations for society.

    Learn more about BIIB800 clinical trial.

  • BIIB074 (vixotrigine)

    Trigeminal neuralgia

    Trigeminal neuralgia is an extremely painful, rare condition usually involving one side of the face. Trigeminal neuralgia is characterized by sudden, brief, stabbing, recurrent episodes of pain which frequently occurs spontaneously but is also commonly evoked by trivial stimuli including washing, talking or brushing teeth (trigger factors). The pain follows one or more branches of the trigeminal nerve, which provides nerve sensation from the mouth, face and the front of the scalp. The intensity, frequency and unpredictability of the pain results in profound effects on the quality of life of patients and their caregivers.

     

    How this investigational therapy could help:

    Vixotrigine is a voltage- and use-dependent sodium channel blocker. It is a centrally and peripherally acting small molecule.

  • BIIB074 (vixotrigine)

    Small fiber neuropathy (SFN)

    Small fiber neuropathy (SFN) is a condition characterized by severe pain attacks that typically begin in the feet or hands. Patients may experience spontaneous burning, itching or shooting pain which may be triggered by stimuli that are ordinarily not painful, such as hot or cold temperatures or light touch. SFN is a neuropathic pain condition which can have different causes, such as diabetes or vitamin B12 deficiency, or the cause may be unknown.

    How this investigational therapy could help:

    Vixotrigine is a voltage- and use-dependent sodium channel blocker. It is a centrally and peripherally acting small molecule.

    Learn more about the clinical trial for BIIB074 in SFN.  

  • BIIB093 (IV glibenclamide)

    Brain Contusion

    Brain contusions (bleeding and surrounding swelling within the brain) are a devastating complication associated with blunt head trauma. Within the first hours or days following a head injury, contusions may expand, via the growth of a hematoma (bleeding) and worsening edema (swelling) in the surrounding brain tissues. This can cause rapid neurologic deterioration, including compression of vital neurologic centers, and in some cases, brain death. Expansion of contusions, which may occur in up to 50 percent of cases, is associated with significant morbidity and mortality after brain injury.

     

    How this investigational therapy could help:

    In pre-clinical studies, BIIB093 (IV glibenclamide) has been shown to block SUR1-TRPM4 channels that contribute to ongoing bleeding in the brain and worsening of edema following brain trauma. BIIB093 is being investigated to see if it may potentially reduce the number of patients who experience expansion of their contusions during their ICU stay.

    Learn more about the BIIB093 clinical trial.

     

  • BIIB104 (AMPA)

    Cognitive impairment associated with schizophrenia (CIAS)

    Acquired from Pfizer Inc. 

    Worldwide there are greater than 20 million people living with schizophrenia and it is estimated that the majority of them live with some degree of cognitive impairment attributable to the disease. When cognition is impaired, processing information, planning, and remembering become difficult or impossible. Cognition can be impaired in multiple neurological diseases and neurocognitive disorders, including schizophrenia. 

    BIIB104 is a first-in-class, Phase 2b ready asset for CIAS

    How this investigational therapy could help:

    BIIB104 is an AMPA receptor potentiator designed to facilitate neurotransmission in the central nervous system, a process which can be disrupted in a number of neurological diseases and neurocognitive disorders, including schizophrenia.

    Learn more about TALLY, a clinical trial for cognitive impairment associated with schizophrenia

  • BIIB124 (SAGE-324)

    Essential Tremor

    Developed in collaboration with Sage Therapeutics, Inc.

    Essential tremor is one of the most common movement disorders in the United States, affecting an estimated 6.4 million Americans. For essential tremor patients, uncontrollable shaking of the hands, head, voice or legs creates difficulty eating, dressing, writing and pursuing other day-to-day tasks.

    Why we believe this investigational drug has the potential to help:

    BIIB124 is an investigational oral neuroactive steroid (NAS) GABAA receptor positive allosteric modulator (PAM). NAS GABAA receptor PAMs bind to both synaptic and extrasynaptic GABAA receptors, enhancing inhibitory activity of the GABAergic system, the major inhibitory neurotransmission system in the brain. GABA is the primary inhibitory neurotransmitter in the central nervous system and plays a critical role in maintaining balanced neuronal activity in the brain. GABA dysregulation has been implicated in the pathophysiology of ET.

  • BIIB131 (TMS-007)

    Stroke

    It is estimated that nearly two million people in the United States and the European Union will have a stroke each year. Stroke is a leading cause of mortality and serious long-term disability. There is a substantial unmet medical need for new therapies that can improve outcomes in acute stroke.

    How this investigational therapy could help:

    BIIB131 (TMS-007) is a plasminogen activator with a novel mechanism of action associated with breaking down blood clots and is believed to inhibit local inflammation at the site of thrombosis. This unique combination could position BIIB131 (TMS-007) as a best in class thrombolytic for individuals with acute ischemic stroke (AIS) with potential for an extended treatment window as compared to current thrombolytic agents.

    BIIB131 (TMS-007) is a small molecule which has previously demonstrated an acceptable safety profile in a Phase 1 study and has also reduced infarct volume (area of dead tissue resulting from failure of blood supply) in experimental, preclinical, embolic and thrombotic stroke models.

    BIIB131 (TMS-007) is currently being evaluated in a double-blind, placebo-controlled Phase 2 study in Japan, designed to investigate the safety and efficacy of a single IV administration of TMS-007 in approximately 90 patients with AIS up to 12 hours after stroke onset. The Phase 2 study initiated with the first patient dosed in February 2018.

  • Orelabrutinib (BTK inhibitor)

    Multiple Sclerosis

    MS causes the body’s immune system to attack myelin, a protective sheath covering nerve fibers. Damage to myelin “short circuits” communication between the brain, spinal cord and other areas of the body, severely impairing such neurological functions as mobility, vision and thinking. Over time, the nerves themselves can become damaged permanently.

    Why we believe this investigational drug has the potential to help:

    Orelabrutinib is a small molecule Bruton’s tyrosine kinase inhibitor (BTKi) that has the potential to inhibit B cell receptor signaling and effector functions, hypothesized to contribute to MS pathogenesis. In addition, BTK has been demonstrated to play a key role in the activation of myeloid cells of the immune system via another receptor of this cell (Fcγ receptor signaling (FcγRs)). This proposed dual mechanism of action is hypothesized to result in greater efficacy than inhibition of B cells alone. With its high kinase selectivity and high penetrance of the central nervous system, orelabrutinib has the potential to be a best-in-class BTK inhibitor for relapsing forms of MS and progressive forms of MS, as well as complementing our existing portfolio.

    Learn more about the orelabrutinib clinical trial.

  • BIIB061 (oral remyelination)

    Multiple Sclerosis (MS)

    MS causes the body’s immune system to attack myelin, a protective sheath covering nerve fibers. Damage to myelin “short circuits” communication between the brain, spinal cord and other areas of the body, severely impairing such neurological functions as mobility, vision and thinking. Over time, the nerves themselves can become damaged permanently.

    How this investigational therapy could help:

    BIIB061 is an oral small molecule that induces growth of the cells that make myelin potentially allowing for the re-myelination and restoration of nerve communication in MS patients.

  • BIIB076 (anti-tau mAb)

    Alzheimer's disease

    Alzheimer’s disease (AD) is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability. It is estimated that more than 25 million individuals are living with AD worldwide1.

    Today we understand that AD is a continuum with a long silent phase that begins years before symptoms appear. As AD progresses, symptoms like memory loss, personality and behavioral changes commonly associated with AD begin to manifest.

     

    How this investigational therapy could help:

    The memory loss and functional decline of AD have been linked to abnormal protein deposits that build up in the brain. Among those proteins are amyloid and tau. Deposits of abnormal tau, so-called neurofibrillary tangles, form in the neurons and are linked to increasing impairment and loss of brain cells associated both with AD and with other neurodegenerative diseases, known as tauopathies, such as progressive supranuclear palsy and frontotemporal dementia. BIIB076 is an antibody targeting tau, the protein that forms the deposits, or tangles, in the brain.

    1 World Health Organization Dementia a Public Health Priority. http://www.who.int/mental_health/publications/dementia_report_2012/en/. Accessed 23 May 2016.

  • BIIB078 (IONIS-C9Rx)

    Amyotrophic lateral sclerosis (ALS)

    Developed in collaboration with Ionis Pharmaceuticals.

    *Option to acquire from Ionis Pharmaceuticals.

    Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that results in the loss of motor neurons in the brain and the spinal cord. Motor neurons provide the ability to move, speak, swallow, and breathe. As the disease progresses, ALS patients gradually lose these abilities.

    How this investigational therapy could help:

    The most commonly inherited cause of ALS is a mutation in the C9orF72 gene. The mutation is a sequence of six nucleotides, which gets repeated hundreds to thousands of times in the disease-causing variants. Mutations in C9orF72 account for about 34 percent of familial ALS cases and 12 percent of all ALS cases.

    BIIB078 targets specific messenger RNA emerging from the C9orf72 gene and degrades it, removing the RNA and preventing production of the abnormal protein it encodes. Importantly, BIIB078 largely preserves the normal C9orf72 protein coming from the gene. Preclinical researchers have found this approach to be useful, decreasing ALS-related pathology in preclinical models and improving behavioral function.

    Learn more about the BIIB078 (IONIS-C9Rx) clinical trial.

  • BIIB080 (tau ASO)

    Alzheimer's disease

    Developed in collaboration with Ionis Pharmaceuticals.

    *Option to acquire from Ionis Pharmaceuticals.

    Alzheimer’s disease (AD) is a progressive neurodegenerative disease that damages healthy cells in the brain causing cognitive impairment and functional disability. It is estimated that more than 25 million individuals are living with AD worldwide1. Today we understand that AD is a continuum with a long silent phase that begins years before symptoms appear. As AD progresses, symptoms like memory loss, personality and behavioral changes commonly associated with AD begin to manifest.

    How this investigational therapy could help:

    The memory loss and functional decline of Alzheimer’s disease have been linked to amyloid plaques and tau tangles, abnormal protein deposits that build up in the brain and in the brain cells. BIIB080 (tau ASO) is an antisense oligonucleotide (ASO) that may reduce production of the tau protein and its accumulation in brain cells, potentially slowing the progress of the disease.

    Learn more about the BIIB080 (tau ASO) clinical trial

    1World Health Organization Dementia a Public Health Priority. http://www.who.int/mental_health/publications/dementia_report_2012/en/. Accessed 23 May 2016. 

  • BIIB091 (BTK inhibitor)

    Multiple sclerosis (MS)

    MS causes the body’s immune system to attack myelin, a protective sheath covering nerve fibers. Damage to myelin “short circuits” communication between the brain, spinal cord and other areas of the body, severely impairing such neurological functions as mobility, vision and thinking. Over time, the nerves themselves can become damaged permanently.

    How this investigational therapy could help:

    BIIB091 selectively inhibits Burton’s tyrosine kinase (BTK), a non-receptor tyrosine kinase that regulates the development and signaling of B cells and myeloid cells hypothesized to contribute to MS pathogenesis. In addition, BTK has been demonstrated to play a key role in the activation of another cell of the immune system, the Myeloid cells via another receptor of this cell (Fcγ receptor signaling (FcγRs)).

    Learn more about the BIIB091 clinical trial.

  • BIIB094 (LRRK2 ASO)

    Parkinson’s disease

    Developed in collaboration with Ionis Pharmaceuticals.

    *Option to acquire from Ionis Pharmaceuticals.

    Parkinson’s disease (PD) is a progressive neurodegenerative disease. It is the second most common neurodegenerative disease, with an estimated 10 million patients with PD worldwide in 2020. Motor symptoms of the disease can include slow movement, rigidity, tremors, and impaired balance, while non-motor symptoms can include cognitive impairment, mood or sleep disorders.

     

    How this investigational therapy could help:

    Research indicates that genetic factors contribute to the complex pathogenesis of Parkinson’s disease, including mutations in the LRRK2 gene. BIIB094 is an antisense oligonucleotide (ASO) designed to bind to LRRK2 mRNA and mediate its degradation, reducing LRRK2 protein levels and potentially slowing disease progression. 

    Learn more about the BIIB094 clinical trial.

  • BIIB100 (XPO1 inhibitor)

    Amyotrophic lateral sclerosis (ALS)

    Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that results in the loss of motor neurons in the brain and the spinal cord. Motor neurons provide the ability to move, speak, swallow, and breathe. As the disease progresses, ALS patients gradually lose these abilities.

    How this investigational therapy could help:

    BIIB100 is an inhibitor of Exportin 1 (XPO1), a protein that mediates export of many proteins and RNA species from the cell nucleus. Dysfunction in nucleocytoplasmic transport (the process by which proteins and RNA molecules move in and out of the nucleus) appears to play a role in ALS and other neurodegenerative diseases.

    BIIB100 is being evaluated to see if it can slow the progression of sporadic ALS by normalizing the nuclear traffic of proteins and RNA.

    Learn more about the BIIB100 clinical trial.

  • BIIB101 (SNCA ASO)

    Multiple System Atrophy (MSA)

    Developed in collaboration with Ionis Pharmaceuticals

    *Option to acquire from Ionis Pharmaceuticals

    Multiple system atrophy (MSA) is a rare, rapidly progressive, ultimately fatal disorder of the central nervous system. Symptoms typically develop in adulthood, usually around 50-60 years old. Motor symptoms of the disease can include slow movement, muscle stiffness, poor muscle coordination and balance. Autonomic symptoms can include low blood pressure, loss of bladder or bowel control, sleep and psychiatric problems.

    How this investigational therapy could help:

    Research indicates that accumulation of alpha-synuclein (SNCA) within the central nervous system leads to neuronal degeneration and loss of neurologic function. BIIB101 is an antisense oligonucleotide (ASO) designed to bind to SNCA mRNA and mediate its degradation, which may reduce SNCA protein levels and potentially slow disease progression. 

    Learn more about BIIB101 clinical trial at https://www.clinicaltrials.gov/ct2/show/NCT04165486?term=biib101&draw=2&rank=1

  • BIIB105 (ATXN2 ASO)

    Amyotrophic lateral sclerosis (ALS)

    Developed in collaboration with Ionis Pharmaceuticals

    *Option to acquire from Ionis Pharmaceuticals

    ALS is a progressive neurodegenerative disease that results in the loss of motor neurons in the brain and the spinal cord. Motor neurons provide the ability to move, speak, swallow, and breathe. As the disease progresses, ALS patients gradually lose these abilities.

    How this investigational therapy could help:

    Preclinical research indicates that Ataxin-2 (ATXN2) is an important modulator of TDP-43 pathology, the key pathology in about 95 percent of ALS cases. Preclinical studies have shown that increasing ATXN2 exacerbates (worsens) TDP-43-mediated death of motor neurons, while decreasing ATXN2 mitigates this toxicity, which may improve functionality and potentially increase survival. BIIB105 is an antisense oligonucleotide (ASO) designed to bind to ATXN2 mRNA and mediate its degradation, which is expected to reduce ATXN2 protein levels and potentially slow disease progression for the broad ALS population.

  • BIIB107 (anti-VLA4)

    Multiple Sclerosis

    MS causes the body’s immune system to attack myelin, a protective sheath covering nerve fibers. Damage to myelin “short circuits” communication between the brain, spinal cord and other areas of the body, severely impairing such neurological functions as mobility, vision and thinking. Over time, the nerves themselves can become damaged permanently.

    Why we believe this investigational drug has the potential to help:

    BIIB107 is a humanized monoclonal antibody that targets α4 integrins, which are essential for leukocyte trafficking into the brain and are an important element in pathology of MS. It’s hypothesized that BIIB107, by disrupting the interaction of α4 integrin and its ligands and therefore preventing leukocyte trafficking into the brain, has the potential to reduce inflammation and provide therapeutic benefit in MS.

    Learn more about the BIIB107 clinical trial.

  • BIIB110 (ActRIIA/B ligand trap)

    Spinal muscular atrophy (SMA)

    Acquired from AliveGen, Inc.

    SMA is a genetic, progressive and often terminal rare disease that affects an individual’s ability to walk, eat and, ultimately, breathe. Debilitating and often fatal, SMA affects approximately one in 10,000 live births and is a leading genetic cause of death among infants.

    How this investigational therapy could help:

    Inhibition of the myostatin pathway is a genetically validated target for muscle enhancement. BIIB110 is a hybrid activin II receptor (ACTIIR) ligand trap that sequesters both myostatin and activins while sparing the related ligand bone morphogen protein 9 (BMP9). This targeted mechanism of action may result in greater muscle mass, function and improved safety compared to other myostatin inhibition approaches. 

  • BIIB118 (CK1 inhibitor)

     Irregular Sleep Wake Rhythm Disorder (ISWRD) in Parkinson’s Disease (PD)

    Parkinson’s disease (PD) is a progressive neurodegenerative disease. It is the second most common neurodegenerative disease, with an estimated 10 million patients with PD worldwide in 2020. Motor symptoms of the disease can include slow movement, rigidity, tremors, and impaired balance, while non-motor symptoms can include cognitive impairment, mood or sleep disorders.

    How this investigational therapy could help:

    BIIB118 is a CNS-penetrant regulator of circadian rhythm with potential to address behavioral and neurological symptoms across various psychiatric and neurological diseases. Biogen plans to develop the Phase 1 asset for the treatment of ISWRD in PD.

    Learn more about BIIB118 clinical trial.

  • BIIB122 (LRRK2 SM)

    Parkinson’s disease

    Developed in collaboration with Denali Therapeutics Inc.

    Parkinson’s disease (PD) is a progressive neurodegenerative disease. It is the second most common neurodegenerative disease, with an estimated 10 million patients with PD worldwide in 2020. Motor symptoms of the disease can include slow movement, rigidity, tremors, and impaired balance, while non-motor symptoms can include cognitive impairment, mood or sleep disorders.

    How this investigational therapy could help:

    Preclinical research indicates that genetic factors may contribute to the complex pathogenesis of Parkinson’s disease, including mutations in the LRRK2 gene. BIIB122 is a selective and brain-penetrant small molecular inhibitor of LRRK2, that may reduce lysosomal dysfunction and potentially slow disease progression. 

    Learn more about the BIIB122 clinical trial

Currently no results for this search